Is BillionToOne, Inc. (NASDAQ:BLLN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating BillionToOne, Inc. at current levels.
A prenatal screening company morphing into a liquid biopsy platform, with the cancer business still treated as a free option.
Where BLLN is headed
BillionToOne reaches 2028 looking nothing like the company Wall Street currently models. UNITY Complete is the prenatal screen of record across the major US OB networks, taking share from Natera's Panorama and LabCorp's offering by doing something neither can match at scale: detecting fetal antigens and recessive conditions in a single tube of maternal blood. That single-tube workflow matters more than the diagnostics crowd seems to grasp, because it collapses what used to be three separate tests with three separate reimbursement fights into one CPT bundle. At roughly 40% revenue growth into FY27 and incremental gross margins north of 75%, the prenatal business alone supports a low-single-digit billion valuation. Everything else is upside.
Read the full Compass Direction on BLLN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $102.39).
See the full BLLN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is BillionToOne, Inc. (NASDAQ:BLLN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating BillionToOne, Inc. at current levels. A prenatal screening company morphing into a liquid biopsy platform, with the cancer business still treated as a free option.
What is BLLN's Compass Score?
BillionToOne, Inc. scores 84/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for BLLN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the BLLN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.